A word from our director:
TB Centre Update and Renewal
As we plan for the next era of the TB Centre, I wish to first take a look back, before providing a glimpse of the future.
The launch of the newly minted McGill International TB Centre was held on March 28, 2013, with a CIHR Cafe-Scientifique. Since then, we successfully obtained McGill Senate approval in December 2014 and then Board of Governors approval in February 2015. At that point, we were ‘real’, and we were officially allowed to call ourselves a McGill Centre, complete with a McGill website. This official status resulted in annual reports, leading to successful annual renewals (including one received just this morning) where we detailed each year an increasing number of members and activities.
As of June 2018, we have 14 full members, 11 regular associates, 4 international-based associates and 1 emeritus member. We are recognized by the UN to send a delegate to this September’s High-Level meeting on TB, we are stakeholders members of the TB alliance, we are on the boards of AERAS and FIND, and we have partnership agreements with Manipal University and TB Reach. In the recent edition of the Global Health Program Summer Institute, TB Centre members directed 5 of the courses. Our students are working everywhere and tweeting about it, while publishing, winning prizes, and more. It is safe to say that we are recognized for our leadership across campus and around the world. We should all be very proud of our collective prominence.
As mentioned earlier this year, I am stepping down as Director to make way for a new team to lead the Centre. We have received four nominations for the renewed TB Centre executive, namely:
Madhukar Pai, Director
Amrita Daftary, Associate Director, Global/Population Health
Faiz Ahmad Khan, Associate Director, Clinical Research
Maziar Divangahi, Associate Director, Fundamental Research.
I think you will all agree that this is an excellent slate of individuals to take over the TB Centre; we all look forward to seeing where they take us next.
I wish to especially thank the Associate Directors (Dick Menzies and Madhu Pai) and Lynn Dery Capes, for their amazing support and guidance spanning process to program, over these past 5 years. And finally, thank you all, in advance, for the new places where we go together in the years to come.
The 6th Annual TB Centre Day was a huge success!
Inuit. His talk was "TB Elimination across Inuit Nunangat" and covered a lot information about the Inuit. This was followed by an Award ceremony then by Wine and Cheese.The day started with trainees giving great Oral Presentations, and after a break over 150 people listened to the keynote address by President Natan Obed of Inuit Tapiriit Kanatami. This is the National organization that represents Canada's 65,000
There was much twitter action and some news coverage of the event.
"We Need To Science The Shit Out Of Tuberculosis"
Madhu Pai's op-ed, based on the 5 minute talk he gave at the UN TB hearing in NYC this week: https://www.huffington post.ca/dr-madhukar-pai/tuberculosis-cure-treatment-research_a_23449596/
The video recording is available here: http://webtv.un.org/meetings-events/general-assembly/watch/part-2-interactive-civil-society-hearing-on-the-fight-against-tuberculosis/5793778501001/?term=#t=13m27s.
Congratulations to our members:
in the most recent FRQS competition:
Congratulations to Dr. Erwin Schurr for being named a Distinguished James McGill Professor
TB-oriented and other courses at the McGill Summer Institute in Infectious Diseases and Global Health
Beyond Killing Tuberculosis
Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease. However, this perspective has recently been challenged as scientists have taken a lesson from plant biologists about an ancient strategy involving the ability to “tolerate” rather than “resist” infection to maintain health. This concept, referred to as “disease tolerance”, provides an opportunity to develop new strategies that mitigate the consequences of infection. Read more
McGill Research influences WHO TB policies
WHO has just released new clinical guidelines for treatment of INH-resistant TB (based in part on the work of Dr Dick Menzies and others at McGill, Montreal). Isoniazid-resistant TB, without concurrent rifampicin resistance, is estimated to occur in about 8% of people with TB globally. A regimen of 6 months rifampicin, ethambutol, pyrazinamide and levofloxacin is now recommended in adults and children diagnosed with this type of drug-resistant TB. Resistance to rifampin and fluoroquinolones should be ruled out before using this regimen.
Introducing N-TB, an app for nutritional assessment & counselling of patients with tuberculosis
On World TB Day, the Center for Nutrition Studies, Yenepoya University, Mangalore in association with McGill International TB Centre, Montreal will announce the public release of N-TB, an android mobile based application for the nutritional assessment and counseling of adult patients with TB. This app, endorsed by the Revised National Tuberculosis Control Programme and WHO India, was included in the new initiatives unveiled by Prime Minister Narendra Modi during the Delhi End TB Summit held in March. Download the App for free on Google Play
Great job at knowledge synthesis by TB Centre researchers:
Just got designated as a ‘Highly cited paper’ by the Web of Science, meaning it is among the top 1% of papers of similar age in the field of clinical medicine! Read it here: http://go.nature.com/2Da2w2q
McGill authors topped the rankings as first and corresponding authors in systematic reviews and meta-analyses in TB research.
According to a study, McGill researchers account for 6% of the world's best cited TB papers which is very high ranking! The 100 top-cited tuberculosis research https://www.atsjournals.org/doi/10.1164/rccm.201707-1489PPstudies (International Union Against Tuberculosis and Lung Disease) Download
Positions in Tuberculosis Research Available:
Selected Recent TB Articles/Publications
A bibliometric analysis of tuberculosis research. 2007-2016. PLoS One
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infect Dis.
- Une réflexion mondiale, une action locale
- Indigenous people deserve better
- Developing Diagnostics for Global Health
- We Need To Science The Shit Out Of Tuberculosis
- Éliminer la tuberculose chez les Inuit d'ici 2030: un objectif ambitieux
- TB infections: Developing tolerance vs.the battle to resist
- TUBERCULOSE : Apprendre à tolérer plutôt que combattre la bactérie
- For First Time, W.H.O. Names Some Lab Tests ‘Essential’
- Beyond Killing Tuberculosis
- Ego is the Enemy, especially for Academics
- Avis de recherche: chefs de file pour un monde exempt de tuberculose
- A new app for nutritional assessment & counselling of patients with TB
- Hope rises for a world free of TB
- India's tuberculosis research contributions get international recognition
- Click here for more
Our centre brings together over 20 investigators with expertise spanning epidemiology, policy setting, economic analyses, implementation research, meta-analyses, qualitative research to basic science in microbiology, host genetics and immune response.
The work is done both at an academic centre and with a number of collaborating groups around the world. On these pages, we introduce the faculty members who are members of our centre and describe our training programs for students. Find out why our Centre is a world leader in the interdisciplinary study of TB and how we work together to unravel the many mysteries of this recalcitrant disease.